Daan G. Knapen

Groningen, GR, Netherlands

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

Tri-specific Humabody CB307 Targeting CD137, Prostate-specific Membrane Antigen, and Human Serum Albumin Whole-body Biodistribution Measured with 89Zr-CB307 PET.

Tri-specific Humabody CB307 Targeting CD137, Prostate-specific Membrane Antigen, and Human Serum Albumin Whole-body Biodistribution Measured with 89Zr-CB307 PET.

Journal: Molecular cancer therapeutics

Published: May 31, 2025

Heterogeneity of CD8 T-Cell Changes in Advanced Melanomas After Initiation of Immunotherapy.

Heterogeneity of CD8 T-Cell Changes in Advanced Melanomas After Initiation of Immunotherapy.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: January 08, 2025

A Phase I Dose Escalation and Cohort Expansion Study of CB307, a Trispecific Humabody against PSMA, CD137, and Albumin in Patients with PSMA-Positive Solid Tumors.

A Phase I Dose Escalation and Cohort Expansion Study of CB307, a Trispecific Humabody against PSMA, CD137, and Albumin in Patients with PSMA-Positive Solid Tumors.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: October 29, 2024

Monoclonal antibody biosimilars for cancer treatment.

Monoclonal antibody biosimilars for cancer treatment.

Journal: iScience

Published: July 08, 2024

Lethal Capecitabine Toxicity in Patients With Complete Dihydropyrimidine Dehydrogenase Deficiency Due to Ultra-Rare DPYD Variants.

Lethal Capecitabine Toxicity in Patients With Complete Dihydropyrimidine Dehydrogenase Deficiency Due to Ultra-Rare DPYD Variants.

Journal: JCO precision oncology

Published: May 06, 2024

Immune checkpoint inhibitor-mediated polymyalgia rheumatica versus primary polymyalgia rheumatica: comparison of disease characteristics and treatment requirement.

Immune checkpoint inhibitor-mediated polymyalgia rheumatica versus primary polymyalgia rheumatica: comparison of disease characteristics and treatment requirement.

Journal: Rheumatology (Oxford, England)

Published: November 02, 2023

Independent transcriptional patterns reveal biological processes associated with disease-free survival in early colorectal cancer.

Independent transcriptional patterns reveal biological processes associated with disease-free survival in early colorectal cancer.

Journal: Communications medicine

Published: April 25, 2023

Potential, Limitations and Risks of Cannabis-Derived Products in Cancer Treatment.

Potential, Limitations and Risks of Cannabis-Derived Products in Cancer Treatment.

Journal: Cancers

Published: March 15, 2023

Opportunities on the horizon for the management of early colon cancer.

Opportunities on the horizon for the management of early colon cancer.

Journal: Critical reviews in oncology/hematology

Published: October 11, 2022

Molecular imaging to support cancer immunotherapy.

Molecular imaging to support cancer immunotherapy.

Journal: Journal for immunotherapy of cancer

Published: July 08, 2022

89Zr-3,2-HOPO-Mesothelin Antibody PET Imaging Reflects Tumor Uptake of Mesothelin-Targeted 227Th-Conjugate Therapy in Mice.

89Zr-3,2-HOPO-Mesothelin Antibody PET Imaging Reflects Tumor Uptake of Mesothelin-Targeted 227Th-Conjugate Therapy in Mice.

Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine

Published: August 19, 2021

Lessons learnt from scoring adjuvant colon cancer trials and meta-analyses using the ESMO-Magnitude of Clinical Benefit Scale V.1.1.

Lessons learnt from scoring adjuvant colon cancer trials and meta-analyses using the ESMO-Magnitude of Clinical Benefit Scale V.1.1.

Journal: ESMO open

Published: January 13, 2020

Showing 1-12 of 16

Last Updated: 09/26/2026